Patient P-03345
Therapy response
Improving
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
96%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S14
- Day 58 SC-12 recommended — Supportive Compound SC-12
- Day 59 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 59 Patient accepted — Started SC-12 in the companion
- Day 65 GI symptom burden −12% vs expected — Supportive Compound SC-12
- Day 71 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 59.
Primary contributors, last 14 days
- Toxicity+12
- GI instability+5
- Treatment adherence+5
What helped?
- Supportive Compound SC-12Day 58Result: symptom burden −12%
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 82% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 41/100
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 73 and rising
- Autonomic recovery ↓45
- WearableResting HR 90 bpm
- WearableShort sleep window
- Inflammatory signalling ↑25
- BloodInflammatory load index 64
- Drug metabolism and exposure ↑20
- BloodToxicity index 57
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Intermediate metabolizerExpected exposure
Microbiome
Shannon diversity 2.8 · butyrate capacity 41/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 40 ms
- Sleep
- 6.7 h
- Steps
- 4,293
- Resting HR
- 86 bpm
Daily log: GI score 73, nutritional resilience 33, adherence 48.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03323 | 50% | S14 | GI-04 | improved | 48 |
| P-03341 | 44% | S14 | NP-02 | improved | 49 |
| P-03049 | 43% | S14 | GI-04 | improved | 49 |
| P-03390 | 42% | S14 | ME-01 | improved | 41 |
| P-03413 | 42% | S14 | ME-01 | improved | 48 |
| P-03037 | 41% | S14 | NP-02 | improved | 43 |
| P-03460 | 41% | S11 | SC-12 | improved | 46 |
| P-03081 | 39% | S10 | GI-04 | improved | 53 |
| P-03030 | 36% | S14 | NP-02 | improved | 43 |
| P-03251 | 35% | S14 | SC-12 | improved | 54 |
| P-03430 | 35% | S14 | SC-12 | improved | 45 |
| P-03070 | 34% | S14 | GI-04 | improved | 51 |